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doi:10.1016/j.fjs.2011.08.016Summary Objective: Early-stage colorectal cancer without lymph node (LN) metastasis is
a disease requiring only surgery, except when it has a high risk. However, inadequate resection
or LN examination is often followed by poor prognosis. In this study, we evaluated the
adequacy of the number of LNs examined with regard to the survival of patients with stage
II colorectal adenocarcinoma.
Methods: Between January 2003 and December 2006, patients with stage II colorectal cancer
were enrolled in this study. Disease progression, background data, including tumor character-
istics, and pathologic factors with an emphasis on the number of LNs examined and nodal
status of the number of nodes variously involved were analyzed and correlated with survival.
Results: A total of 190 patients were included in our study. Using the receiver-operating char-
acteristic curve and multivariate Cox proportional hazard regression analysis, we found that
better overall survival was significantly associated with examination of >15 LNs (HR Z 0.15,
p Z 0.001) and T3 stage (HR Z 3.393, p Z 0.024).
Conclusions: In this study, patients with stage II colorectal adenocarcinoma who had >15 LNs
examined and were stage T3 had a better prognosis. In other words, we believe that examina-
tion of 12 LNs is not a sufficient number for evaluation of overall survival of such patients. We
should follow-up patients with fewer examined LNs more closely.
Copyright ª 2011, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
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Table 1 Pertinent patient data
Characteristics Patient number (%)
Mean age (y) 64.6  11.9
65 y 84
<65 y 106
Gender
Male 106 (55.8)
Female 50 (44.2)
Mean survival, mo (range) 65.1 (62.2e68.0)
Median follow-up time, mo (range) 42.4 (2.4e74.4)
Number of examined LNs
Mean  SD (range) 14.6  7.6 (2e42)
>15 77 (41)
15 113 (59)
Tumor location
Colon 140 (73.7)
Rectum 50 (26.3)
Preoperative CEA level
5 ng/mL 63 (33)
<5 ng/mL 118 (62)
Tumor differentiation
Well 24 (12.6)
Moderate 140 (73.7)
Poor 26 (13.7)
T-Stage
T3 181 (95)
T4 9 (5)
Tumor type
Adenocarcinoma 185 (97)
Mucinous adenocarcinoma 5 (3)
Lymphovascular invasion
Yes 20 (11)
No 170 (89)
Postoperative adjuvant chemotherapy
Yes 78 (41)
No 112 (59)
Disease recurrence
Yes 37 (21)
No 153 (79)
Mortality
Yes 7 (4)
No 173 (96)
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Colorectal cancer is the second leading cause of cancer
deaths in the United States.1 In Taiwan, it ranks third in
cancer deaths but second in incidence.
Surgical treatment is the mainstay of curative treatment.
Adequate surgery means an en bloc resection of the tumor
with a wide safe margin. In addition, lymph node (LN)
dissection should be performed along lymphatic drainage.
Recently, evaluation of 12 LNs has beenmandated to prevent
colon cancer understaging.2,3 As indicated by the National
Comprehensive Cancer Network guidelines, adjuvant
chemotherapy should not be delivered to patients with
node-negative colorectal cancer (including stages I and II)
except for patients with a high risk.
With this treatment guideline, however, inadequate
node assessment will lead to undertreatment and result in
poor outcome, particularly for node-negative patients due
to a lack of further treatment following an operation.
In our study, therefore, we have attempted to find
a relation between the number of examined LNs and the
survival of patients with node-negative stage II colorectal
cancer.
2. Methodology
Patients with colorectal cancer who had undergone surgical
intervention were enrolled from January 2003 to December
2006 in a referral tertiary medical center in southern
Taiwan. This study was approved by the IRB at our hospital.
A complete medical history and thorough physical
examination were performed for each patient, who also
had an abdominal computed tomography scan preopera-
tively. All patients underwent surgery. We performed
radical resection for colorectal cancer with LN dissection.
All specimens were carefully checked and reported.
Patients with preoperative bowel perforation or
obstruction, and those who received preoperative chemo-
therapy and/or radiotherapy, inadequate surgical treat-
ment or surgical mortality cases were excluded from this
study.
The correlations between the patients’ basic data, labo-
ratory data, pathologic results, and survival were evaluated.
For the convenience of data analysis, each patient’s age
and gender were recorded. Preoperative carcinoembryonic
antigen (CEA) level was divided into two categories:
CEA  5 ng/mL and CEA < 5 ng/mL. Pathologic staging was
determined according to the American Joint Committee on
Cancer system (sixth edition). Tumor differentiation was
classified as moderate and poor. The number of examined
LNs, T-stage, lymphovascular invasion (LVI), and adjuvant
therapy were also included in this investigation.
Overall survival was defined as the length of time from
the date of operation to the date of death or the last visit at
our outpatient department.
Data were expressed as mean  standard deviation (SD).
Logistic regression and the receiver-operating character-
istic (ROC)4 curve were used for statistics based on the
number of examined LNs. The ROC curve is a method used
to express the relation and trade-off between sensitivity
and specificity. It can be used as an aid to decide where thebest cut-off value should be. The univariate and multivar-
iate Cox proportional hazard regression analyses were used
to assess statistical significance among all groups. Multi-
variate Cox proportional hazard regression analysis pre-
dicting overall survival was performed. The final model was
conducted using the forward stepwise model selection
method from the candidate predictors with p < 0.1 in the
univariate analysis. Finally, all data were analyzed using
SPSS statistical software (SPSS for Windows, Version 16,
Figure 1 Receiver-operating characteristic (ROC) curve
using LN Z 15 with overall survival cut-off value Z 15,
sensitivityZ 47.1%, specificityZ 90.9%. Area under curvature
(AUC) Z 0.731, p < 0.001.
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ered statistically significant.
3. Results
During the period from January 2003 to December 2006,
data for 709 colorectal cancer patients were recorded in
a database. For this study, 190 patients with stage II colo-
rectal cancer were selected from the database by exclusion
criteria. There were 106 males (55.8%) and 84 females
(44.2%). Ages (mean  SD) were 64.6  11.9 years (range
29e89 years). Median follow-up time was 42.4 monthsTable 2 Univariate Cox proportional hazard regression analysis
Age (y) 65 vs. <65
Sex Female vs. male
Tumor location Rectum vs. colon
Preoperative CEA
CEA (ng/mL) 5 vs. <5
Differentiation Well vs. poor
Moderate vs. poor
LN total >15 vs. 15
>12 vs. 12
Tumor type Mucinous vs. adenocarcinoma
T-stage T4 vs. T3
LVI Yes vs. no
Adjuvant therapy Yes vs. no
CEA Z carcinoembryonic antigen; CI Z confidence interval; HR Z ha(2.4e74.4 months). Disease recurrence was noted in 37
patients (21%) and mortality in 7 patients (4%). The average
number of examined LNs was 14.6  7.6. There were 77
patients with >15 LNs examined. T3 tumor stage was found
in 181 patients and adenocarcinoma was diagnosed in 185
patients. Lymphovascular invasion was found in 20 patients
(10.5%). Adjuvant therapy was delivered to 78 patients
(Table 1).
Using logistic regression and the ROC curve, we found
that the number of examined LNs of >15 or <15 was the
most meaningful cut-point value for prediction of progress
of overall survival [sensitivityZ 47.1%, specificityZ 90.9%,
area under curvature (AUC) Z 0.731] (Figure 1).
Using univariate Cox proportional hazard regression
analysis, for overall survival, we found that age [hazard
ratio (HR) Z 2.29, p Z 0.034], number of examined
LNs > 15 (HR Z 0.15, p Z 0.001), T3 lesion (HR Z 2.91,
p Z 0.046), and administration of adjuvant therapy
(HR Z 0.37, p Z 0.019) were significantly associated with
a better outcome (Table 2).
Moreover, when using multivariate Cox proportional
hazard regression analysis, we found that number of
examined LNs > 15 (HR Z 0.15, p Z 0.001) and T3 stage
(HR Z 0.29, p Z 0.024) were independent factors of
a better outcome for overall survival (Table 3).
4. Discussion
Accurate LN examination is crucial because nodal status is
an important prognostic factor.5,6 In America, patients with
node-negative colon cancer have a 5-year survival of >75%,
whereas patients with node-positive disease have a 5-year
survival rate of only around 50%. In addition, node metas-
tasis status also affects the further delivery of chemo-
therapy, which could improve survival by approximately
30% for patients with node-positive disease.7,8 Patients with
stage II colorectal cancer are node-negative, and chemo-
therapy is not suggested except when the disease is
complicated.
In this study, for overall survival, the number of exam-
ined nodes >15 and T3 stage were factors that indicatedfor overall survival
HR 95% CI for HR p
Lower Upper
2.29 1.07 4.93 0.034
0.94 0.47 1.87 0.862
0.74 0.32 1.71 0.486
1.00 0.98 1.01 0.610
0.69 0.31 1.55 0.369
0.942 0.251 3.532 0.929
0.832 0.316 2.189 0.709
0.15 0.05 0.48 0.001
0.29 0.13 0.64 0.002
1.56 0.21 11.49 0.661
2.91 1.02 8.32 0.046
1.77 0.68 4.58 0.243
0.37 0.16 0.85 0.019
zard ratio; LN Z lymph node; LVI Z lymphovascular invasion.
Table 3 Multivariate Cox proportional hazard regression analysis conducted using forward stepwise model selection method
HR 95% CI for HR p
Lower Upper
LN total >15 vs. 15 0.14 0.04 0.46 0.001
T-Stage T4 vs. T3 3.54 1.24 10.12 0.019
Adjuvant therapy Yes vs. No 0.48 0.20 1.16 0.104
Age (y) 65 vs. <65 1.32 0.58 2.98 0.512
CI Z confidence interval; HR Z hazard ratio; LN Z lymph node.
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previously suggested number of examined LNs was consid-
ered to improve the overall survival of patients with node-
negative colon cancer. Several recent studies have shown
that the greater the number of examined nodes, the better
the outcome.9,10 In Taiwan, the situation is similar. Tsai
et al27 found that >18 examined LNs and T-stage are factors
for better overall survival. However, T-stage in their study
was divided into T2 and T3 þ T4 groups, thus differing from
the present study. The larger number of nodes examined
may indicate that staging is more accurate, and thus
patients will not be undertreated. In other words, fewer
nodes examined may potentially have more positive nodes
that are either not resected or not included in the spec-
imen. During data analysis, the number of LNs examined
(>12 or <12) was also included. The results showed that
12 LNs is also an indicator during univariate analysis
(HRZ 0.29, p Z 0.002). However, with the ROC curve, we
found that 15 LNs is better than 12 LNs (sensitivityZ 59.2%,
specificity Z 75.8%) in predicting prognosis.
T-Stage was another independent factor for overall
survival in our study. Several published articles have shown
that advanced T-stage has a strong likelihood of having
positive nodes and approximately 8e12% of T1 tumors and
14% of T2 tumors are node-positive.11e13 Another explana-
tion is that T4 patients have a poor prognosis when
compared with early stage III (T1-2N1M0).14 Misclassifica-
tion for such T4 patients would result in micrometastasis
without treatment.
Several studies have shown that LVI is a strong stage-
independent prognostic factor.15e18 The presence of LVI is
associated with an increased risk of regional LN meta-
stasis.19e21 Lim et al22 also revealed that LVI is an inde-
pendent factor for unfavorable prognosis. In our present
study, however, no significant difference was associated
with the presence of LVI. It may be because our pathologic
examination was performed by different pathologists. They
used only hematoxylin and eosin (H&E) for staining and
fewer slides for diagnosis. Kingston et al23 found that H&E
staining proved less sensitive in identification of LVI. The
poorer sensitive stain and fewer slides might have led to
a small number of LVI in our patients (10.5%); however, in
another study 26.6% T3-stage and 43.5% T4-stage patients
were documented.22
In this study, adjuvant therapy was a significant prog-
nostic factor for overall survival in univariate analysis but
failed to show significance in multivariate analysis. This
finding is similar to that of a meta-analysis by Gill et al
indicating that adjuvant therapy slightly improves disease-
free survival but not overall survival.24 Adjuvant therapyshould be considered in stage II patients with high risk,
including inadequately sampled nodes, T4 lesions, perfo-
ration, poorly differentiated tumor, lymphovascular or
perineural invasion, close-positive, indeterminate or posi-
tive margins, and bowel obstruction, which are also known
to carry a higher rate of recurrence.25,26
The limitations in this study include the nature of the
retrospective design. In general, the date of death in each
case was recorded, but the cause of death was not avail-
able in some cases. Thus, in some cases we could not
confirm whether the death was disease-related or not.
5. Conclusions
This study showed that long-term outcomes expressed by
cancer deaths after attempted curative resection for stage
II colon cancer were significantly improved by increasing
lymph node retrieval and examination. Statistically, our
results show that 12 examined LNs is not large enough for
prediction of overall survival and suggest that examination
of >15 LNs is associated with a significant increase in
overall survival. This supports the current clinical practice
of harvesting and analyzing as many nodes as possible
during surgical resection for pathologic analysis, particu-
larly in stage II patients.Acknowledgments
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